Loading...
XTAE
ALMD
Market cap9mUSD
Dec 04, Last price  
32.90ILS
1D
4.78%
1Q
2.81%
Jan 2017
-71.56%
IPO
-98.73%
Name

Allmed Solutions Ltd

Chart & Performance

D1W1MN
XTAE:ALMD chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
315.46%
Rev. gr., 5y
16.57%
Revenues
0k
2,563,0002,669,0004,701,0004,916,0005,178,0007,353,0007,703,0009,279,00011,147,0009,719,0005,545,000000
Net income
-9m
L
-14,067,000-29,787,000-50,005,000-24,644,000-20,932,000-23,917,000-22,679,000-20,175,00021,988,000-10,893,0001,457,000-11,193,0001,422,000-8,752,000
CFO
-8m
L
-13,097,000-29,374,000-13,407,000-19,026,000-15,874,000-17,271,000-18,417,000-16,024,000-12,329,000-8,817,000-5,477,000-10,215,0007,136,000-8,025,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Allium Medical Solutions Ltd. develops, manufactures, and sells long-term, fully covered, expandable, and retrievable stents for the treatment of the various obstructions in the urinary and GI tract in Israel and internationally. The company offers ureteric, bulbar, triangular and round prostatic, and biliary stents. Allium Medical Solutions Ltd. is based in Caesarea, Israel.
URL
https://www.allium-medical.com/
IPO date
Feb 01, 2007
Employees
19
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT